Targovax ASA: First quarter 2018 results
Oslo, Norway, 3 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its first quarter 2018 results. A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET (details below). HIGHLIGHTS FOR THE FIRST QUARTER 2018 Research & Development · In January, Targovax announced that ONCOS-102 generated immune activation at both the systemic and lesional levels in checkpoint inhibitor (CPI) refractory melanoma in four out of the first four patients treated ·